by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Limbic-predominant age-related TAR DNA-binding protein of 43 kDa encephalopathy neuropathologic change (LATE-NC) staging criteria were updated in 2023. We evaluated this updated staging using National Alzheimer’s Coordinating Center data....
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract Introduction The angiotensin-converting enzyme 2 (ACE2), which is expressed in cerebral vascular endothelial cells (CVECs), has been currently identified as a functional receptor for SARS-CoV-2. Methods We specifically induced injury to ACE2-expressing CVECs...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Biomarkers for Alzheimer’s disease neuropathologic change (ADNC) have been instrumental in developing effective disease-modifying therapeutics. However, to prevent/treat dementia effectively, we require biomarkers for non-AD...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Blood-based biomarkers offer a promising approach for the detection of neuropathologies from repetitive head impacts (RHI). We evaluated plasma biomarkers of amyloid, tau, neurodegeneration, and inflammation in former football players. METHODS...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Understanding the impact of biomarker-based dementia risk estimation in people with mild cognitive impairment (MCI) and their care partners is critical for patient care. METHODS MCI patients and study partners were counseled on Alzheimer’s...
